Embecta Q2 Earnings Call Highlights

Disappointing Q2 and lower guidance: Consolidated revenue fell about 14.4% year-over-year to roughly $222 million, GAAP net loss was $4.1 million, and Embecta cut fiscal 2026 revenue guidance to $1.015–1.035 billion while trimming adjusted operating margin and EPS guidance to 22.25–23.25% and $1.55–$1.75, respectively.

U.S. pen needle weakness drove most of the shortfall: Management said about $75 million of the organic revenue reduction is tied largely to pen needles (≈$53 million), with nearly half of that from share loss at a single customer and the rest from retail market softness, pricing pressure and inventory cuts.

Strategic moves to diversify and shore up capital: Embecta plans to close the Owen Mumford acquisition (adding ~ $30 million in expected revenue), authorized up to $100 million in buybacks while cutting the dividend to $0.01, raised its adjusted tax rate and lowered free cash flow guidance to $95–105 million as it prioritizes debt reduction (targeting ~$150 million repaid in 2026).

Interested in Embecta Corp.? Here are five stocks we like better.

Embecta (NASDAQ:EMBC) reported fiscal second-quarter 2026 results that fell short of expectations, driven primarily by U.S. weakness in its pen needle business, and lowered its full-year outlook while outlining actions aimed at stabilizing performance and accelerating a broader diversification strategy.

Chairman and CEO Dev Kurdikar said the quarter was “difficult,” with consolidated revenue down 14.4% year-over-year on an as-reported basis, or down 17.4% on an adjusted constant-currency basis. The company’s international performance was “in line with our prior outlook,” he said, but the U.S. business “fell short of expectations.”

→ Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook

Embecta revised fiscal 2026 revenue guidance to a range of $1.015 billion to $1.035 billion, down from its prior range of $1.071 billion to $1.093 billion. The updated range includes about $30 million of expected revenue from the pending acquisition of Owen Mumford, which Embecta expects to close by the end of the month. Excluding that contribution, Kurdikar said the organic revenue outlook at the midpoint is about $995 million, a reduction of roughly $75 million from the low end of prior expectations.

Kurdikar attributed the largest portion of the U.S. year-over-year decline to pen needle share loss “most of which is concentrated at a single customer,” with the remainder spread across smaller regional and independent pharmacy customers. He emphasized that patients switching to competitive products are “likely not on payer plans where we have preferred access,” which he said makes the revenue impact larger than what an average unit price would indicate.

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

The second-largest contributor, he said, was “overall market volume softness for insulin pens and pen needles in the retail channel.” Embecta is seeing signs of declining insulin pen prescriptions, driven by the retail channel, though partially mitigated by growth in long-term care. He also pointed to additional pressure from patients buying pen needles in channels where Embecta does not participate or where products are lower priced, as well as inventory reductions at certain accounts and added net pricing pressure.

In discussing the guidance reduction, Kurdikar said pen needles represent about 70% of the $75 million reduction, or roughly $53 million. He estimated that share loss accounts for nearly half of the pen needle revenue reduction, about $25 million, while market volume softness accounts for about $20 million. The remaining pen needle headwinds, including inventory reductions and pricing pressure, represent about $8 million of the reduction.

→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries

Syringes were another factor, accounting for about $13 million of the remaining $22 million reduction outside pen needles, “most of which stems from lower syringe use associated with compounded drugs,” Kurdikar said. He also noted Embecta’s decision to discontinue alcohol swabs after its sole supplier of the active ingredient exited API manufacturing in late 2025; Embecta was unable to qualify an alternate supplier under FDA standards. Kurdikar said discontinuing swabs accounts for about $5 million of the revenue guidance reduction, and slower estimated growth in safety products accounts for another roughly $4 million.

The company’s guidance assumes share loss and market softness persist through the remainder of the year “without any further deterioration or recovery,” Kurdikar said. In response to the magnitude of the reduction, he said Embecta has initiated a review of its cost structure and organizational footprint, with findings to be communicated in future quarterly reporting.

CFO Jake Elguicze reported second-quarter revenue of approximately $222 million. U.S. revenue totaled about $95 million, a decline of 29.4% on an adjusted constant-currency basis, while international revenue was about $126 million, up 2.1% as reported but down 4.1% on an adjusted constant-currency basis.

International results were in line with expectations, Elguicze said, with lower revenue in China due to “ongoing market dynamics and the broader geopolitical and trade environment,” partially offset by strength in Latin America, Asia, and Canada.

By product family on an adjusted constant-currency basis, Elguicze said:

Contract manufacturing revenue declined 43.2%

GAAP gross profit was $127.8 million with a 57.6% margin, compared with $164.1 million and a 63.4% margin a year earlier. On an adjusted basis, gross profit was $131.8 million and margin was 59.4%, down from $165 million and 63.7% in the prior-year period. Elguicze said the decline was primarily driven by lower U.S. revenue and lower China revenue, partially offset by net changes in profit and inventory adjustments and foreign exchange.

GAAP operating income was $35 million (15.8% margin), down from $62.9 million (24.3% margin) a year earlier. Adjusted operating income was $48.6 million (21.9% margin), down from $81.4 million (31.4% margin). Elguicze said the decline in adjusted operating income was driven by the drop in adjusted gross profit, as operating expenses were consistent with the prior year.

On the bottom line, Embecta posted a GAAP net loss of $4.1 million, or a loss per diluted share of $0.07, versus GAAP net income of $23.5 million, or $0.40 per diluted share, in the prior-year quarter. Adjusted net income was $16.1 million, or $0.27 per share, compared with $40.7 million, or $0.70 per share, a year earlier.

For fiscal 2026, Embecta lowered adjusted operating margin guidance to 22.25% to 23.25%, down from 29% to 30%, and reduced adjusted EPS guidance to $1.55 to $1.75 from $2.80 to $3.00. Elguicze said the largest driver was lower U.S. revenue and associated gross profit. He added that Owen Mumford, including interest expense on associated borrowings, is expected to be dilutive to adjusted EPS by about $0.15.

Embecta also now expects an adjusted tax rate of about 28%, up from about 23%, which Elguicze said would reduce adjusted EPS versus prior expectations by about $0.10.

Kurdikar said the Owen Mumford acquisition is intended to accelerate Embecta’s shift toward becoming a “broad-based medical supplies company” serving pharmaceutical partners and chronic care patients across multiple therapy areas. Owen Mumford is a privately held U.K.-based medical device developer with a 70-year track record, Kurdikar said, and generated approximately GBP 69.4 million in revenue in fiscal 2025, with about 80% concentrated in the U.K. and U.S.

He said Owen Mumford’s revenue mix is about 60% medical devices and 40% pharmaceutical services, with pharmaceutical services viewed as the higher-growth segment. Kurdikar highlighted Owen Mumford’s Aidaptus autoinjector platform, describing it as a “next generation autoinjector” designed to accommodate both 1 ml and 2.25 ml fill volumes with a single form factor and final assembly process.

The deal structure includes an upfront payment of GBP 100 million at closing and up to an additional GBP 50 million in performance-based payments tied to Aidaptus net sales, Kurdikar said. Embecta assumed “a modest level of operational synergies” in its model, but no revenue synergies, while noting potential opportunity given Embecta’s presence in more than 100 countries.

Separately, Kurdikar said Embecta’s board authorized a three-year share repurchase program of up to $100 million and reduced the quarterly dividend to $0.01 per share from $0.15 per share. He said the changes are intended to provide flexibility to deploy capital toward share repurchases or additional debt reduction, which he described as the company’s current primary focus areas.

Elguicze said Embecta generated about $47 million in free cash flow in the six months ended March 31, 2026, and repaid $75 million of debt. He said last-12-month net leverage was approximately 3x, below the credit facility covenant requirement of 4.75x. Despite the outlook reduction, he said Embecta continues to target repaying about $150 million in debt during 2026. Updated free cash flow guidance is $95 million to $105 million, down from $180 million to $200 million, and includes about $40 million of one-time cash use associated with the brand transition and the Owen Mumford acquisition.

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

The article "Embecta Q2 Earnings Call Highlights" was originally published by MarketBeat.